Literature DB >> 26553768

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Kenneth C Anderson, Melissa Alsina, Djordje Atanackovic, J Sybil Biermann, Jason C Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y Krishnan, Shaji K Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P Treon, Donna Weber, Joachim Yahalom, Dorothy A Shead, Rashmi Kumar.   

Abstract

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Recent statistics from the American Cancer Society indicate that the incidence of MM is increasing. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) included in this issue address management of patients with solitary plasmacytoma and newly diagnosed MM.
Copyright © 2015 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2015        PMID: 26553768      PMCID: PMC4891187          DOI: 10.6004/jnccn.2015.0167

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  178 in total

Review 1.  Radiotherapy in the management of plasma cell tumors.

Authors:  K Hu; J Yahalom
Journal:  Oncology (Williston Park)       Date:  2000-01       Impact factor: 2.990

2.  A gene expression signature for high-risk multiple myeloma.

Authors:  R Kuiper; A Broyl; Y de Knegt; M H van Vliet; E H van Beers; B van der Holt; L el Jarari; G Mulligan; W Gregory; G Morgan; H Goldschmidt; H M Lokhorst; M van Duin; P Sonneveld
Journal:  Leukemia       Date:  2012-05-08       Impact factor: 11.528

3.  Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.

Authors:  Robert M Rifkin; Stephanie A Gregory; Ann Mohrbacher; Mohamad A Hussein
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

4.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

Authors:  Murielle Roussel; Valérie Lauwers-Cances; Nelly Robillard; Cyrille Hulin; Xavier Leleu; Lotfi Benboubker; Gérald Marit; Philippe Moreau; Brigitte Pegourie; Denis Caillot; Christophe Fruchart; Anne-Marie Stoppa; Catherine Gentil; Soraya Wuilleme; Anne Huynh; Benjamin Hebraud; Jill Corre; Marie-Lorraine Chretien; Thierry Facon; Hervé Avet-Loiseau; Michel Attal
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

Review 5.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

6.  High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.

Authors:  Jean-Paul Fermand; Sandrine Katsahian; Marine Divine; Veronique Leblond; Francois Dreyfus; Margaret Macro; Bertrand Arnulf; Bruno Royer; Xavier Mariette; Edouard Pertuiset; Coralie Belanger; Maud Janvier; Sylvie Chevret; Jean Claude Brouet; Philippe Ravaud
Journal:  J Clin Oncol       Date:  2005-11-07       Impact factor: 44.544

7.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.

Authors:  Bart Barlogie; Michel Attal; John Crowley; Frits van Rhee; Jackie Szymonifka; Philippe Moreau; Brian G M Durie; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

8.  Erythropoietin treatment of anemia associated with multiple myeloma.

Authors:  H Ludwig; E Fritz; H Kotzmann; P Höcker; H Gisslinger; U Barnas
Journal:  N Engl J Med       Date:  1990-06-14       Impact factor: 91.245

9.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

10.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

View more
  21 in total

1.  Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.

Authors:  Bita Fakhri; Mark A Fiala; Sascha A Tuchman; Tanya M Wildes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01-31

2.  A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Kenneth C Anderson; Paola Neri; Bruno Paiva; Mehmet Samur; Meletios Dimopoulos; Margarita Kulakova; Annette Lam; Mahmoud Hashim; Jianming He; Bart Heeg; Jon Ukropec; Jessica Vermeulen; Sarah Cote; Nizar Bahlis
Journal:  Blood Adv       Date:  2020-12-08

Review 3.  Bisphosphonates in multiple myeloma: an updated network meta-analysis.

Authors:  Rahul Mhaskar; Ambuj Kumar; Branko Miladinovic; Benjamin Djulbegovic
Journal:  Cochrane Database Syst Rev       Date:  2017-12-18

Review 4.  An Evidence-Based Approach to Myeloma Bone Disease.

Authors:  Nicholas Bingham; Antonia Reale; Andrew Spencer
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 3.952

5.  Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.

Authors:  Li-Wen Huang; Wendi Bacon; Constance Cirrincione; Bercedis Peterson; Gwynn Long; David Rizzieri; Keith M Sullivan; Kelly Corbet; Mitchell Horwitz; Nelson Chao; Cristina Gasparetto; Sascha A Tuchman
Journal:  Hematol Oncol       Date:  2017-01-19       Impact factor: 5.271

6.  Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.

Authors:  Vanessa Piechotta; Tina Jakob; Peter Langer; Ina Monsef; Christof Scheid; Lise J Estcourt; Sunday Ocheni; Sebastian Theurich; Kathrin Kuhr; Benjamin Scheckel; Anne Adams; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2019-11-25

Review 7.  Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.

Authors:  Jing-di Liu; Chun-Yan Sun; Liang Tang; Ying-Ying Wu; Qing-Yun Wang; Bei Hu; Yu Hu
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

8.  Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies.

Authors:  Joshua D Brown; Val R Adams
Journal:  Healthcare (Basel)       Date:  2016-02-26

9.  Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma.

Authors:  Joshua D Brown; Val R Adams; Daniela C Moga
Journal:  Healthcare (Basel)       Date:  2016-12-20

10.  Acquired haemophilia a secondary to multiple myeloma: management of a patient with a mechanical mitral valve.

Authors:  Lisa B Pinchover; Rami Alsharif; Talia Bernal
Journal:  BMJ Case Rep       Date:  2020-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.